96 related articles for article (PubMed ID: 3133627)
1. A novel 53 kDa protein complexed with P210bcr-abl in human chronic myelogenous leukemia cells.
Li WJ; Kloetzer WS; Arlinghaus RB
Oncogene; 1988 Jun; 2(6):559-66. PubMed ID: 3133627
[TBL] [Abstract][Full Text] [Related]
2. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
Maxwell SA; Kurzrock R; Parsons SJ; Talpaz M; Gallick GE; Kloetzer WS; Arlinghaus RB; Kouttab NM; Keating MJ; Gutterman JU
Cancer Res; 1987 Mar; 47(6):1731-9. PubMed ID: 2434223
[TBL] [Abstract][Full Text] [Related]
3. P210 BCR-ABL is complexed to P160 BCR and ph-P53 proteins in K562 cells.
Campbell ML; Li W; Arlinghaus RB
Oncogene; 1990 May; 5(5):773-6. PubMed ID: 2140598
[TBL] [Abstract][Full Text] [Related]
4. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
Danhauser-Riedl S; Warmuth M; Druker BJ; Emmerich B; Hallek M
Cancer Res; 1996 Aug; 56(15):3589-96. PubMed ID: 8758931
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
6. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia.
Kaur G; Gazit A; Levitzki A; Stowe E; Cooney DA; Sausville EA
Anticancer Drugs; 1994 Apr; 5(2):213-22. PubMed ID: 8049505
[TBL] [Abstract][Full Text] [Related]
7. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R
J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645
[TBL] [Abstract][Full Text] [Related]
8. Phosphotyrosine phosphatase activity prevents the detection of P210bcr/abl protein in mature cells in chronic myelogenous leukemia even by an immunoblotting technique.
Shibata K; Nishimura J; Takahira H; Nawata H
Leukemia; 1989 Sep; 3(9):615-9. PubMed ID: 2474729
[TBL] [Abstract][Full Text] [Related]
9. Establishment, characterization, and chromosomal analysis of new leukemic cell lines derived from MT/p210bcr/abl transgenic mice.
Honda H; Ohno S; Takahashi T; Takatoku M; Yazaki Y; Hirai H
Exp Hematol; 1998 Mar; 26(3):188-97. PubMed ID: 9502614
[TBL] [Abstract][Full Text] [Related]
10. Model mice for BCR/ABL-positive leukemias.
Honda H; Hirai H
Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
[TBL] [Abstract][Full Text] [Related]
11. Differences in tyrosine phosphorylated proteins between cells expressing P210bcr/abl and P190bcr/abl.
Nishimura J; Shibata K; Sadamura S; Takahira H; Hirata J; Umemura T; Nawata H; Okamura J
Int J Hematol; 1992 Jun; 55(3):227-33. PubMed ID: 1379843
[TBL] [Abstract][Full Text] [Related]
12. Characterization of bcr gene products in hematopoietic cells.
Li WJ; Dreazen O; Kloetzer W; Gale RP; Arlinghaus RB
Oncogene; 1989 Feb; 4(2):127-38. PubMed ID: 2648252
[TBL] [Abstract][Full Text] [Related]
13. Two bcr/abl fusion gene products, P210bcr/abl and P190bcr/abl, are equally sensitive to the protein tyrosine phosphatase of mature granulocytes.
Nishimura J; Okamura J; Shibata K; Takahira H; Yufu Y; Kato S; Hirata J; Umemura T; Nawata H
Int J Hematol; 1991 Dec; 54(6):471-8. PubMed ID: 1793829
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of tumor promoters on P210bcr-abl expression.
Li WJ; Smith LA; Kabat KG; Kloetzer WS; Arlinghaus RB
Hematol Pathol; 1989; 3(3):113-23. PubMed ID: 2687223
[TBL] [Abstract][Full Text] [Related]
15. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
Brusa G; Benvenuti M; Mazzacurati L; Mancini M; Pattacini L; Martinelli G; Barbieri E; Greenberger JS; Baccarani M; Santucci MA
Haematologica; 2003 Jun; 88(6):622-30. PubMed ID: 12801837
[TBL] [Abstract][Full Text] [Related]
16. Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
Guo JQ; Hirsch-Ginsberg CF; Xian YM; Stass SA; Champlin RE; Giralt SA; McCredie KB; Campbell ML; Arlinghaus RB
Hematol Pathol; 1993; 7(2):91-106. PubMed ID: 8340287
[TBL] [Abstract][Full Text] [Related]
17. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
Snyder DS; Wu Y; McMahon R; Yu L; Rossi JJ; Forman SJ
Biol Blood Marrow Transplant; 1997 Oct; 3(4):179-86. PubMed ID: 9360779
[TBL] [Abstract][Full Text] [Related]
18. Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice.
Mizuno T; Yamasaki N; Miyazaki K; Tazaki T; Koller R; Oda H; Honda ZI; Ochi M; Wolff L; Honda H
Oncogene; 2008 May; 27(24):3465-74. PubMed ID: 18193087
[TBL] [Abstract][Full Text] [Related]
19. Detection of P210bcr-abl in mature granulocytes from Ph1-positive chronic myelogenous leukemia patients by an immunoblotting method.
Kuwao F; Takahashi I
Leukemia; 1993 Aug; 7(8):1168-73. PubMed ID: 8350617
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
